Xando Díaz-Villamarín

732 total citations
17 papers, 161 citations indexed

About

Xando Díaz-Villamarín is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Xando Díaz-Villamarín has authored 17 papers receiving a total of 161 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 4 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Xando Díaz-Villamarín's work include Antiplatelet Therapy and Cardiovascular Diseases (5 papers), Retinal Diseases and Treatments (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). Xando Díaz-Villamarín is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (5 papers), Retinal Diseases and Treatments (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). Xando Díaz-Villamarín collaborates with scholars based in Spain, Netherlands and United Kingdom. Xando Díaz-Villamarín's co-authors include Cristina Lucía Dávila-Fajardo, Luis Javier Martínez-González, J Cabeza Barrera, Alba Antúnez-Rodríguez, Jesús Sánchez-Ramos, Rocío Morón, Jesse J. Swen, Christina Mitropoulou, Kariofyllis Karamperis and George P. Patrinos and has published in prestigious journals such as PLoS ONE, Biomedicine & Pharmacotherapy and International Journal of Cardiology.

In The Last Decade

Xando Díaz-Villamarín

16 papers receiving 160 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xando Díaz-Villamarín Spain 9 69 53 36 26 24 17 161
Steven E. Gryn Canada 9 95 1.4× 44 0.8× 71 2.0× 38 1.5× 25 1.0× 13 212
Innocent G. Asiimwe United Kingdom 8 39 0.6× 67 1.3× 15 0.4× 14 0.5× 19 0.8× 19 159
Amber L. Beitelshees United States 6 70 1.0× 94 1.8× 22 0.6× 41 1.6× 22 0.9× 7 176
Carmen Wiley United States 9 69 1.0× 47 0.9× 40 1.1× 68 2.6× 23 1.0× 15 302
Shamin Mohd Saffian Malaysia 10 44 0.6× 38 0.7× 12 0.3× 12 0.5× 26 1.1× 33 177
Irena Druce Canada 4 184 2.7× 56 1.1× 104 2.9× 53 2.0× 29 1.2× 9 300
Kun-Tai Lee Taiwan 11 402 5.8× 39 0.7× 35 1.0× 31 1.2× 48 2.0× 18 511
Marco Chirico Italy 6 38 0.6× 183 3.5× 65 1.8× 96 3.7× 32 1.3× 14 289
Ramón Brugada Spain 9 242 3.5× 48 0.9× 55 1.5× 52 2.0× 84 3.5× 17 329
Shane Rowan United States 7 364 5.3× 24 0.5× 19 0.5× 13 0.5× 78 3.3× 11 434

Countries citing papers authored by Xando Díaz-Villamarín

Since Specialization
Citations

This map shows the geographic impact of Xando Díaz-Villamarín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xando Díaz-Villamarín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xando Díaz-Villamarín more than expected).

Fields of papers citing papers by Xando Díaz-Villamarín

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xando Díaz-Villamarín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xando Díaz-Villamarín. The network helps show where Xando Díaz-Villamarín may publish in the future.

Co-authorship network of co-authors of Xando Díaz-Villamarín

This figure shows the co-authorship network connecting the top 25 collaborators of Xando Díaz-Villamarín. A scholar is included among the top collaborators of Xando Díaz-Villamarín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xando Díaz-Villamarín. Xando Díaz-Villamarín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Díaz-Villamarín, Xando, María Jesús Martínez-Pérez, Emilio Fernández-Varón, et al.. (2025). Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine. Journal of Personalized Medicine. 15(6). 245–245. 1 indexed citations
2.
Díaz-Villamarín, Xando, María Jesús Martínez-Pérez, Emilio Fernández-Varón, et al.. (2025). Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics. 17(5). 542–542. 1 indexed citations
3.
Martínez-Pérez, María Jesús, Rocío Morón, Xando Díaz-Villamarín, et al.. (2024). Selective Digestive Decontamination: A Comprehensive Approach to Reducing Nosocomial Infections and Antimicrobial Resistance in the ICU. Journal of Clinical Medicine. 13(21). 6482–6482. 3 indexed citations
4.
Díaz-Villamarín, Xando, Emilio Fernández-Varón, José Luís Callejas-Rubio, et al.. (2023). Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation. Biomedicine & Pharmacotherapy. 168. 115706–115706. 10 indexed citations
5.
Díaz-Villamarín, Xando, Kariofyllis Karamperis, Athanassios Vozikis, et al.. (2023). Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study. Human Genomics. 17(1). 51–51. 15 indexed citations
6.
Díaz-Villamarín, Xando, et al.. (2022). Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients. Pharmaceutics. 14(8). 1555–1555. 4 indexed citations
7.
Díaz-Villamarín, Xando, et al.. (2022). Pharmacogenetics of siponimod: A systematic review. Biomedicine & Pharmacotherapy. 153. 113536–113536. 13 indexed citations
8.
Díaz-Villamarín, Xando, et al.. (2021). Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients. Pharmaceutics. 13(11). 1973–1973. 3 indexed citations
9.
Díaz-Villamarín, Xando, Alba Antúnez-Rodríguez, Eduardo Moreno Escobar, et al.. (2021). Pharmacogenetic polymorphisms affecting bisoprolol response. Biomedicine & Pharmacotherapy. 142. 112069–112069. 12 indexed citations
10.
Díaz-Villamarín, Xando, et al.. (2020). Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis. Genes. 11(11). 1335–1335. 11 indexed citations
11.
Dávila-Fajardo, Cristina Lucía, et al.. (2019). Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. Genes. 10(4). 261–261. 15 indexed citations
12.
Díaz-Villamarín, Xando, et al.. (2018). 5PSQ-028 Cardiovascular risk factor in individuals with gender identity disorder or cross-sex hormone therapy. HighWire Press Open Archive. A177.1–A177. 2 indexed citations
13.
14.
15.
Sánchez-Ramos, Jesús, et al.. (2016). Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. International Journal of Cardiology. 225. 289–295. 40 indexed citations
16.
Tong, Hoi Y., Cristina Lucía Dávila-Fajardo, Alberto M. Borobia, et al.. (2016). A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS ONE. 11(3). e0150456–e0150456. 16 indexed citations
17.
Díaz-Villamarín, Xando, Cristina Lucía Dávila-Fajardo, Luis Javier Martínez-González, et al.. (2016). Genetic Polymorphisms Influence on the Response to Clopidogrel in Peripheral Artery Disease Patients Following Percutaneous Transluminal Angioplasty. Pharmacogenomics. 17(12). 1327–1338. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven E. Gryn Breakdown of academic impact, for papers by Innocent G. Asiimwe Breakdown of academic impact, for papers by Amber L. Beitelshees Breakdown of academic impact, for papers by Carmen Wiley Breakdown of academic impact, for papers by Shamin Mohd Saffian Breakdown of academic impact, for papers by Irena Druce Breakdown of academic impact, for papers by Kun-Tai Lee Breakdown of academic impact, for papers by Marco Chirico Breakdown of academic impact, for papers by Ramón Brugada Breakdown of academic impact, for papers by Shane Rowan
Rankless by CCL
2026